The 2023 American Academy of Dermatology (AAD) Annual Meeting was held Thursday, March 16 – Tuesday, March 21, 2023, in New Orleans, LA, and is the largest dermatology meeting in the world, showcasing over 1,000 expert speakers and over 300 sessions. This report includes 13 summaries of talks focusing on psoriasis.
Commentary: Psoriasis comprehensive review
Lars Iversen, MD, DMSc
Aarhus University Hospital
Aarhus, Denmark
IPC Board Member
PUBLICATION
Psoriasis. Griffiths C, Armstrong A, Gudjonsson J, Barker J. Lancet. vol. 397. no. 10281. 2021 Apr; 397: 1301–15. doi: 10.1016/s0140-6736(20)32549-6.
COMMENTARY
In the April 2021 issue of the Lancet, four of our esteemed colleagues in the IPC published an updated and comprehensive review of the current pieces of knowledge on psoriasis.
It is a very well-written review covering all aspects of psoriasis spanning from epidemiology and pathophysiology to clinical presentation, associated diseases, and the management of psoriasis. Alongside an update of the most recently published literature in the field of psoriasis, the manuscript is also accompanied by clear clinical pictures, figures that elegantly explain the pathogenesis of psoriasis, and tables that provide a good overview of the different treatment options.
The review is up-to-date and discusses the current knowledge and challenges in managing psoriasis during the SARS-CoV-2 pandemic and nicely points out future directions of psoriasis research by highlighting unresolved questions, new developments, and unmet medical needs. Because of the comprehensive nature of this manuscript, it appeals to those who want to gain an overview of the various aspects of psoriasis and those who are searching for an in-depth understanding of specific aspects of psoriasis and its subtypes such as their different pathophysiologies.
This manuscript will undoubtedly serve as a critical reference paper in the field of psoriasis in the coming years.
Categories
Recent Posts
Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Mona El-Kalioby, MBBCh, MSc, MD
Psoriasis and the Pandemic: Lessons Learned from PsoProtect
Boehringer Ingelheim’s SPEVIGO® Receives Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA)
Also Read
Commentary: Preclinical and Clinical Evidence for Suppression of Alcohol Intake by Apremilast
A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.
Opportunities and Limitations of Telemedicine in the Diagnosis and Treatment of Psoriasis
The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.
Focus on Psoriasis: A Report from the 2023 American Academy of Dermatology (AAD) Annual Meeting
The 2023 American Academy of Dermatology (AAD) Annual Meeting was held Thursday, March 16 – Tuesday, March 21, 2023, in New Orleans, LA, and is the largest dermatology meeting in the world, showcasing over 1,000 expert speakers and over 300 sessions. This report includes 13 summaries of talks focusing on psoriasis.
Subscribe to the IPC Newsletter